The biomarkers consortium: Public and private sectors working in partnership to improve the public health

Oncologist

Volumn 12, Issue 3, 2007, Pages 250-252

  Zerhouni, Elias A ^a   Sanders, Charles A ^a   Von Eschenbach, Andrew C ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; CHOLESTEROL; FLUORODEOXYGLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD PRESSURE; CANCER DIAGNOSIS; CANCER THERAPY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; HEALTH CARE ORGANIZATION; HUMAN; LUNG NON SMALL CELL CANCER; NOTE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PUBLIC HEALTH SERVICE; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

BIOLOGICAL MARKERS; CONGRESSES; COOPERATIVE BEHAVIOR; HUMANS; INTERPROFESSIONAL RELATIONS; MODELS, ORGANIZATIONAL; PRIVATE SECTOR; PUBLIC HEALTH; PUBLIC SECTOR; UNITED STATES;

EID: 34147109828     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-3-250     Document Type: Note

References (0)